These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 27598348)

  • 21. Neurologic and Cognitive Outcomes in Sickle Cell Disease from Infancy through Adolescence.
    Mayer SL; Fields ME; Hulbert ML
    Neoreviews; 2021 Aug; 22(8):e531-e539. PubMed ID: 34341160
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute complications of sickle cell disease in children.
    Drug Ther Bull; 2001 May; 39(5):33-7. PubMed ID: 11396389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of hydroxyurea treatment for patients with hemoglobin SC disease.
    Luchtman-Jones L; Pressel S; Hilliard L; Brown RC; Smith MG; Thompson AA; Lee MT; Rothman J; Rogers ZR; Owen W; Imran H; Thornburg C; Kwiatkowski JL; Aygun B; Nelson S; Roberts C; Gauger C; Piccone C; Kalfa T; Alvarez O; Hassell K; Davis BR; Ware RE
    Am J Hematol; 2016 Feb; 91(2):238-42. PubMed ID: 26615793
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Practice patterns of stroke screening and hydroxyurea use in children with sickle cell disease: a survey of health care providers.
    Madden NA; Jones GL; Kalpatthi R; Woods G
    J Pediatr Hematol Oncol; 2014 Aug; 36(6):e382-6. PubMed ID: 24714503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sickle cell disease.
    Yardumian A; Crawley C
    Clin Med (Lond); 2001; 1(6):441-6. PubMed ID: 11792081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical complications in severe pediatric sickle cell disease and the impact of hydroxyurea.
    Tripathi A; Jerrell JM; Stallworth JR
    Pediatr Blood Cancer; 2011 Jan; 56(1):90-4. PubMed ID: 20922765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease.
    Kassim AA; DeBaun MR
    Expert Opin Pharmacother; 2014 Feb; 15(3):325-36. PubMed ID: 24392871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current and emerging treatments for sickle cell disease.
    Monus T; Howell CM
    JAAPA; 2019 Sep; 32(9):1-5. PubMed ID: 31460979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolution of sickle cell disease from a life-threatening disease of children to a chronic disease of adults: The last 40 years.
    Chaturvedi S; DeBaun MR
    Am J Hematol; 2016 Jan; 91(1):5-14. PubMed ID: 26547630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging disease-modifying therapies for sickle cell disease.
    Carden MA; Little J
    Haematologica; 2019 Sep; 104(9):1710-1719. PubMed ID: 31413089
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neurocognitive functioning in preschool children with sickle cell disease.
    Heitzer AM; Cohen DL; Okhomina VI; Trpchevska A; Potter B; Longoria J; Porter JS; Estepp JH; King A; Henley M; Kang G; Hankins JS
    Pediatr Blood Cancer; 2022 Mar; 69(3):e29531. PubMed ID: 34971013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proponent or collaborative: Physician perspectives and approaches to disease modifying therapies in sickle cell disease.
    Bakshi N; Sinha CB; Ross D; Khemani K; Loewenstein G; Krishnamurti L
    PLoS One; 2017; 12(7):e0178413. PubMed ID: 28727801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined hydroxyurea and ET
    Taylor C; Kasztan M; Tao B; Pollock JS; Pollock DM
    Acta Physiol (Oxf); 2019 Feb; 225(2):e13178. PubMed ID: 30144292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gastrointestinal and hepatic complications of sickle cell disease.
    Ebert EC; Nagar M; Hagspiel KD
    Clin Gastroenterol Hepatol; 2010 Jun; 8(6):483-9; quiz e70. PubMed ID: 20215064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature].
    Nkashama GM; Wakamb GK; Mulangu AM; Nkashama GM; Kupa BK; Numbi OL
    Pan Afr Med J; 2015; 21():124. PubMed ID: 26327961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia.
    Gladwin MT; Kato GJ
    Hematology Am Soc Hematol Educ Program; 2005; ():51-7. PubMed ID: 16304359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sickle cell disease in North Europe.
    Howard J; Davies SC
    Scand J Clin Lab Invest; 2007; 67(1):27-38. PubMed ID: 17365983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathology of sickle cell disease.
    Malowany JI; Butany J
    Semin Diagn Pathol; 2012 Feb; 29(1):49-55. PubMed ID: 22372205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble Fas/FasL ratio as a marker of vasculopathy in children and adolescents with sickle cell disease.
    Adly AA; Ismail EA; Andrawes NG; Mahmoud MM; Eladawy R
    Cytokine; 2016 Mar; 79():52-8. PubMed ID: 26765484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.